You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GDP

Showing 1 - 25 of 133
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

B-cell Lymphoma Trial in Belgium, France (selinexor, Rituximab, Dexamethasone)

Completed
  • B-cell Lymphoma
  • Bruxelles, Belgium
  • +7 more
Dec 6, 2021

Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

Recruiting
  • Treatment
  • Peripheral T-cell Lymphoma
  • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
  • Beijing, China
  • +4 more
Jun 28, 2022

Lymphoma, Non-Hodgkin's Trial in Toronto (Obinutuzumab, Gemcitabine, Dexamethasone)

Completed
  • Lymphoma, Non-Hodgkin's
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Apr 11, 2021

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

Traumatic Stress, Post-Traumatic Growth Trial in Karachi (GDP)

Completed
  • Traumatic Stress, Post-Traumatic Growth
  • GDP
  • Karachi, Sindh, Pakistan
    Shamoon Noushad
Aug 10, 2021

NK/T Cell Lymphoma Trial in Singapore (IV Nivolumab, IV Gemcitabine, IV Cisplatin)

Withdrawn
  • NK/T Cell Lymphoma
  • IV Nivolumab
  • +4 more
  • Singapore, Singapore
    National Cancer Centre Singapore
Nov 3, 2020

Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in Worldwide (Selinexor (combination therapy), Placebo matching for

Recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • Selinexor (combination therapy)
  • +7 more
  • Chandler, Arizona
  • +51 more
May 6, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell

Unknown status
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • CEOP/IVE/GDP chemotherapy regimen
  • CEOP chemotherapy regimen for 6 cycles
  • Fuzhou, Fujian, China
  • +3 more
Mar 7, 2020

Hypertension in Guangdong Province(GDP Study)

Recruiting
  • Hypertension
  • Cardiovascular Diseases
  • Non-interventional study
  • Guangzhou, Guangdong, China
  • +1 more
Jan 10, 2020

Lymphoma, B-Cell Trial in Vancouver, Toronto, Montreal (Venetoclax, RiTUXimab Injection, Rituximab SC)

Recruiting
  • Lymphoma, B-Cell
  • Vancouver, British Columbia, Canada
  • +2 more
Jan 24, 2022

Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Standard of Care
  • JCAR017
  • Phoenix, Arizona
  • +78 more
Jan 13, 2023

Oral Manifestations Trial in Hong Kong (Home oral excrise)

Recruiting
  • Oral Manifestations
  • Home oral excrise
  • Hong Kong, Hong Kong SAR, Hong Kong
    Faculty of Dentisry, the University of Hong Kong
Oct 12, 2022

Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
  • Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
  • La Jolla, California
  • +66 more
Jan 6, 2023

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Lymphoma Trial in Canada (cisplatin, dexamethasone, gemcitabine HCl)

Completed
  • Lymphoma
  • Calgary, Alberta, Canada
  • +12 more
Apr 7, 2020

s of Root Canal Complexity and Clinician Training on Root Canal

Completed
  • Root Canal Infection
  • Root Canal Treatment/ Re-treatment
  • (no location specified)
Dec 12, 2022

Burns Trial in Aurora (Fresh Frozen Plasma)

Recruiting
  • Burns
  • Fresh Frozen Plasma
  • Aurora, Colorado
    University of Colorado Denver Anschutz Medical Campus
Feb 22, 2022

Healthy Trial in Poznan (Cardio-pulmonary exercise test)

Completed
  • Healthy
  • Cardio-pulmonary exercise test
  • Poznań, Poland
    Poznan University of Physical Education
Nov 10, 2021

Diffuse Large B Cell Lymphoma, Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Seoul (azacitidine plus

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • azacitidine plus R-GDP
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 23, 2018

Osteoporosis, Postmenopausal Trial in London (Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®))

Recruiting
  • Osteoporosis, Postmenopausal
  • Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
  • London, United Kingdom
    Centre for Oral Clinical Research, Institute of Dentistry, Barts
Feb 10, 2022